Bio-Rad Laboratories, Inc. (BIO) reported second-quarter 2026 revenue of $651 million, slightly below the prior year but above expectations. Sales were supported by a modest improvement in gross profit, which rose to $345.8 million, even as operating profit eased to $72.6 million.
The company posted strong bottom-line results, with net income attributable to common shareholders increasing to $371.4 million and diluted earnings per share climbing to $13.85. That performance came in well ahead of the $1.77 analyst estimate for EPS.
Cash generation remained positive, with operating cash flow of $98.7 million. Bio-Rad also ended the quarter with $517 million in cash and cash equivalents, up sharply from a year earlier, while total liabilities were little changed at $3.08 billion.
- Revenue: $651 million
- Net income attributable to common shareholders: $371.4 million
- Diluted EPS: $13.85
- Operating cash flow: $98.7 million
- Cash and cash equivalents: $517 million
The stock fell 1.97% after market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Bio-Rad Laboratories, Inc. Hedge Fund Activity
We have seen 160 institutional investors add shares of Bio-Rad Laboratories, Inc. stock to their portfolio, and 185 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VERITAS ASSET MANAGEMENT LLP removed 543,335 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $151,454,631
- CAPITAL WORLD INVESTORS added 450,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $125,437,500
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 388,300 shares (-98.0%) from their portfolio in Q2 2026, for an estimated $114,008,763
- FULLER & THALER ASSET MANAGEMENT, INC. removed 259,577 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $72,357,088
- BARCLAYS PLC added 254,341 shares (+1038.4%) to their portfolio in Q1 2026, for an estimated $70,897,553
- PARNASSUS INVESTMENTS, LLC removed 254,305 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $74,666,491
- NOMURA HOLDINGS INC added 217,342 shares (+inf%) to their portfolio in Q1 2026, for an estimated $60,584,082
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Bio-Rad Laboratories, Inc. Government Contracts
We have seen $4,100,445 of award payments to $BIO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PATHOLOGY TESTING REQUIREMENT: $718,533
- LYPHOCHEK WHOLE BLOOD METALS CONTROL - QUALITY CONTROL REAGENTS: $405,324
- SEROLOGICAL AUTOMATED ANALYZERS FOR HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS TESTING FOR MILITARY...: $349,963
- IMMUNOLOGY: $235,226
- REAGENTS AND LABORATORY CONSUMABLES: $177,154
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Bio-Rad Laboratories, Inc. Price Targets
Multiple analysts have issued price targets for $BIO recently. We have seen 3 analysts offer price targets for $BIO in the last 6 months, with a median target of $300.0.
Here are some recent targets:
- Dan Leonard from RBC Capital set a target price of $320.0 on 05/15/2026
- Brandon Couillard from Wells Fargo set a target price of $290.0 on 05/01/2026
- Patrick Donnelly from Citigroup set a target price of $300.0 on 04/07/2026
